<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    9682041
   </pmid>
   <datecreated>
    <year>
     1998
    </year>
    <month>
     08
    </month>
    <day>
     04
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1998
    </year>
    <month>
     08
    </month>
    <day>
     04
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     14
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0028-4793
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       339
      </volume>
      <issue>
       5
      </issue>
      <pubdate>
       <year>
        1998
       </year>
       <month>
        Jul
       </month>
       <day>
        30
       </day>
      </pubdate>
     </journalissue>
     <title>
      The New England journal of medicine
     </title>
     <isoabbreviation>
      N. Engl. J. Med.
     </isoabbreviation>
    </journal>
    <articletitle>
     Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
    </articletitle>
    <pagination>
     <medlinepgn>
      292-9
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Osteoporosis is a common complication of long-term glucocorticoid therapy for which there is no well-proved preventive or restorative treatment.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      We carried out two 48-week, randomized, placebo-controlled studies of two doses of alendronate in 477 men and women, 17 to 83 years of age, who were receiving glucocorticoid therapy. The primary end point was the difference in the mean percent change in lumbar-spine bone density from base line to week 48 between the groups. Secondary outcomes included changes in bone density of the hip, biochemical markers of bone turnover, and the incidence of new vertebral fractures.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      The mean (+/-SE) bone density of the lumbar spine increased by 2.1+/-0.3 percent and 2.9+/-0.3 percent, respectively, in the groups that received 5 and 10 mg of alendronate per day (P&lt;0.001) and decreased by 0.4+/-0.3 percent in the placebo group. The femoral-neck bone density increased by 1.2+/-0.4 percent and 1.0+/-0.4 percent in the respective alendronate groups (P&lt;0.01) and decreased by 1.2+/-0.4 percent in the placebo group (P&lt;0.01). The bone density of the trochanter and total body also increased significantly in the patients treated with alendronate. There were proportionally fewer new vertebral fractures in the alendronate groups (overall incidence, 2.3 percent) than in the placebo group (3.7 percent) (relative risk, 0.6; 95 percent confidence interval, 0.1 to 4.4). Markers of bone turnover decreased significantly in the alendronate groups (P&lt;0.001). There were no differences in serious adverse effects among the three groups, but there was a small increase in nonserious upper gastrointestinal effects in the group receiving 10 mg of alendronate.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Alendronate increases bone density in patients receiving glucocorticoid therapy.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Internal Medicine, University of Iowa College of Medicine, Iowa City 52242-1081, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Saag
      </lastname>
      <forename>
       K G
      </forename>
      <initials>
       KG
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Emkey
      </lastname>
      <forename>
       R
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Schnitzer
      </lastname>
      <forename>
       T J
      </forename>
      <initials>
       TJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Brown
      </lastname>
      <forename>
       J P
      </forename>
      <initials>
       JP
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hawkins
      </lastname>
      <forename>
       F
      </forename>
      <initials>
       F
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Goemaere
      </lastname>
      <forename>
       S
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Thamsborg
      </lastname>
      <forename>
       G
      </forename>
      <initials>
       G
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Liberman
      </lastname>
      <forename>
       U A
      </forename>
      <initials>
       UA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Delmas
      </lastname>
      <forename>
       P D
      </forename>
      <initials>
       PD
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Malice
      </lastname>
      <forename>
       M P
      </forename>
      <initials>
       MP
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Czachur
      </lastname>
      <forename>
       M
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Daifotis
      </lastname>
      <forename>
       A G
      </forename>
      <initials>
       AG
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <grantlist completeyn="Y">
     <grant>
      <grantid>
       RR00059
      </grantid>
      <acronym>
       RR
      </acronym>
      <agency>
       NCRR NIH HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
    </grantlist>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
     <publicationtype>
      Research Support, U.S. Gov't, P.H.S.
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     N Engl J Med
    </medlineta>
    <nlmuniqueid>
     0255562
    </nlmuniqueid>
    <issnlinking>
     0028-4793
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Glucocorticoids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      53-03-2
     </registrynumber>
     <nameofsubstance>
      Prednisone
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      66376-36-1
     </registrynumber>
     <nameofsubstance>
      Alendronate
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2000 Aug 3;343(5):365-6
     </refsource>
     <pmid version="1">
      10928896
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged, 80 and over
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Alendronate
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bone Density
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Glucocorticoids
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Osteoporosis
     </descriptorname>
     <qualifiername majortopicyn="N">
      chemically induced
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prednisone
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Spinal Fractures
     </descriptorname>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1998
     </year>
     <month>
      7
     </month>
     <day>
      31
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1998
     </year>
     <month>
      7
     </month>
     <day>
      31
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1998
     </year>
     <month>
      7
     </month>
     <day>
      31
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     9682041
    </articleid>
    <articleid idtype="doi">
     10.1056/NEJM199807303390502
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

